The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B 2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting

Once-daily (od), low-dose aspirin (75-100 mg) is recommended to reduce the thrombotic risk of patients with essential thrombocytemia (ET). This practice is based on data extrapolated from other high-risk patients and an aspirin trial in polycythemia vera, with the assumption of similar aspirin pharm...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood cancer journal (New York) 2018-06, Vol.8 (6), p.49
Hauptverfasser:	De Stefano, Valerio, Rocca, Bianca, Tosetto, Alberto, Soldati, Denise, Petrucci, Giovanna, Beggiato, Eloise, Bertozzi, Irene, Betti, Silvia, Carli, Giuseppe, Carpenedo, Monica, Cattaneo, Daniele, Cavalca, Viviana, Dragani, Alfredo, Elli, Elena, Finazzi, Guido, Iurlo, Alessandra, Lanzarone, Giuseppe, Lissandrini, Laura, Palandri, Francesca, Paoli, Chiara, Rambaldi, Alessandro, Ranalli, Paola, Randi, Maria Luigia, Ricco, Alessandra, Rossi, Elena, Ruggeri, Marco, Specchia, Giorgina, Timillero, Andrea, Turnu, Linda, Vianelli, Nicola, Vannucchi, Alessandro M, Rodeghiero, Francesco, Patrono, Carlo
Format:	Artikel
Sprache:	eng
Schlagworte:	Aspirin - administration & dosage Biomarkers Clinical Protocols Disease Management Female Humans Male Patient Selection Platelet Aggregation Inhibitors - administration & dosage Research Design Thrombocythemia, Essential - complications Thrombocythemia, Essential - diagnosis Thrombosis - blood Thrombosis - diagnosis Thrombosis - etiology Thrombosis - prevention & control Thromboxane B2 - blood
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!